Last reviewed · How we verify

NCT04190407

Intravenous Access Time in Pediatric Patients

Completed NA Last updated 11 December 2019
What this trial tests

NA trial testing Intravenous access in Intravenous Access in 84 participants. Completed in 31 January 2018.

Timeline
1 January 2017
Primary endpoint
1 January 2018
31 January 2018

Quick facts

Lead sponsorIstanbul Medeniyet University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment84
Start date1 January 2017
Primary completion1 January 2018
Estimated completion31 January 2018

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Medeniyet University

Who can join

Adults 2 Months to 11, any sex, with Intravenous Access or Pediatric Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In pediatric patients with no vascular access, anesthesia induction is usually achieved with sevoflurane. The aim of investigators to evaluate the optimum intravenous access time and the corresponding bispectral index (BIS) value in pediatric surgery under sevoflurane anesthesia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Investigation of the Optimum Time for Intravenous Access After Anesthesia Induction with Sevoflurane in Pediatric Patients Without Premedication.
    Orhon ZN, Orhon C. · · 2020 · PMID 32733756 · DOI 10.5222/mmj.2020.22309

Verify or expand the search:

Other trials of Intravenous access

Trials testing the same drug.

Other Istanbul Medeniyet University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04190407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing